Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.
A number of other analysts have also commented on CPRX. Bank of America reaffirmed a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday. Truist Financial lifted their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. HC Wainwright increased their price target on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Stephens assumed coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $32.86.
Check Out Our Latest Report on CPRX
Catalyst Pharmaceuticals Stock Performance
Insider Activity
In other news, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the transaction, the insider now owns 51,391 shares of the company’s stock, valued at $1,167,603.52. The trade was a 18.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Molly Harper sold 17,500 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 79,500 shares of company stock worth $1,754,140. Insiders own 11.00% of the company’s stock.
Institutional Investors Weigh In On Catalyst Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in CPRX. GAMMA Investing LLC boosted its stake in Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 681 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter valued at $50,000. Larson Financial Group LLC increased its holdings in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 2,994 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Catalyst Pharmaceuticals in the 2nd quarter worth about $70,000. Finally, Quantbot Technologies LP purchased a new position in Catalyst Pharmaceuticals in the 3rd quarter worth about $151,000. Institutional investors own 79.22% of the company’s stock.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
See Also
- Five stocks we like better than Catalyst Pharmaceuticals
- Golden Cross Stocks: Pattern, Examples and Charts
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- 5 Top Rated Dividend Stocks to Consider
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.